TON - August 2019, Vol 12, No 4

From the Editor - TON August 2019
The August issue of The Oncology Nurse-APN/PA (TON) is filled with important news and insights for today’s oncology nurse. We begin our coverage with a profile of the Fox Chase Cancer Center, Philadelphia, PA, as we speak with Elizabeth Capaldi, RN, BSN, OCN, who discusses her role as a nurse in the center’s infusion room, the significant life events that influenced her choice to become an oncology nurse, the rewards of her job, and what she finds exciting in the evolving field of oncology. Read More ›

Fox Chase Cancer Center (Fox Chase) is a National Cancer Institute–designated Comprehensive Cancer Center research facility and hospital located in Philadelphia, PA. It is part of the Temple University Health System and has a staff of 2400 plus more than 250 volunteers. The world-class center employs top cancer specialists who are dedicated to diagnosing, treating, and managing all types of cancer. Fox Chase is consistently highly rated among cancer centers in the United States. Read More ›

Preserving Sexual Function in Women After Cancer Treatment
Anaheim, CA—The primary reason that nurses cite for not approaching the topic of sexual health with their patients is lack of knowledge. At the Oncology Nursing Society (ONS) 44th Annual Congress, Lisa Chism, DNP, APRN, NCMP, FAANP, Clinical Director, Women’s Wellness Clinic, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, set out to change that by arming oncology nurses with enough knowledge to broach the subject confidently with their female patients. Read More ›

Chicago, IL—The addition of the ­cyclin-dependent kinase (CDK)4/CDK6 inhibitor ribociclib to standard endocrine therapy significantly extended overall survival (OS) compared with endocrine therapy alone in premenopausal women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to results of the phase 3 MONALEESA-7 clinical trial, presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Read More ›

Chicago, IL—With 475 cell and gene therapy companies in North America representing a business enterprise with approximately $20 billion, new immunotherapies are moving rapidly from the laboratory to the clinic. As chimeric antigen receptor (CAR) T-cell therapy makes its way from the academic to the community setting, however, appropriate resources and infrastructure are required to ensure the safe and effective management of patients. Read More ›

Noteworthy Numbers: Bone Cancer
Primary bone cancer is rare, accounting for <0.2% of all new cancers diagnosed in the United States. Read More ›

What to Expect with USP 800: Implementing Safe Handling Practices of Hazardous Drugs
Anaheim, CA—In 2016, the US Pharmacopeia (USP) published standards for safe handling practices of hazardous drugs, aimed at minimizing the exposure risk for healthcare personnel, patients, and the workplace environment. This set of standards is commonly known as the Safe Handling of Hazardous Drugs (USP 800). Read More ›

Creating a Compassionate Workplace: Promoting Civility in Oncology Nursing
Anaheim, CA—Compassion fatigue is a unique response to caregiving professions, and is a natural and normal consequence of caring for patients who are suffering or traumatized, according to Susan B. Childress, MN, RN, OCN, Director of Nursing Services, Huntsman Cancer Institute (HCI), Salt Lake City, UT. Read More ›

On June 10, 2019, the FDA accelerated the approval of polatuzumab vedotin-piiq (Polivy; Genentech), a CD79b-directed antibody-drug conjugate, in combination with bendamustine (Bendeka, Treanda) plus rituximab (Rituxan or a biosimilar; BR) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after ≥2 previous therapies. Read More ›

On July 3, 2019, the FDA granted accelerated approval to selinexor (Xpovio; Karyopharm Therapeutics), a nuclear export inhibitor, in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (MM) who had received ≥4 previous therapies and whose disease is resistant to several other forms of treatment, including ≥2 proteasome inhibitors, ≥2 immunomodulatory agents, and an anti-CD38 monoclonal antibody. Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: